Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.

Cancer science - 1 Jul 2016

Kawamura Takahisa, Kenmotsu Hirotsugu, Taira Tetsuhiko, Omori Shota, Nakashima Kazuhisa, Wakuda Kazushige, Ono Akira, Naito Tateaki, Murakami Haruyasu, Mori Keita, Nakajima Takashi, Ohde Yasuhisa, Endo Masahiro, Takahashi Toshiaki

Abstract excerpt

Although third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) can overcome T790M-mediated resistance in non-small-cell lung cancer (NSCLC), rebiopsy to confirm T790M status is occasionally difficult. We aimed to investigate the current tendency and the limitations of rebiopsy in clinical practice. This study included 139 consecutive NSCLC patients with EGFR mutations, who had...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Resistance, Neoplasm

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 27145431
DOI: 10.1111/cas.12963
PMCID: PMC4946719

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.PMID 27145431Read ↗

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.Semantic proximity Read ↗

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.Semantic proximity Read ↗

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.Semantic proximity Read ↗

Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.Semantic proximity Read ↗

Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.Semantic proximity Read ↗

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.Semantic proximity Read ↗

Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.Semantic proximity Read ↗

Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.Semantic proximity Read ↗

Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.Semantic proximity Read ↗

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).Semantic proximity Read ↗

Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.